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Background
In early development stages of biologicals there is often
more than one molecule against a specific target. A careful
candidate evaluation is crucial to choose an optimal lead
variant for further development. Complex biologicals are
typically produced in CHO cells and host cells as well as
the process are known to influence important molecule
features such as glycan patterns or activity. To streamline
the generation of stable producer cell lines we have estab-
lished an Flp-based RMCE system in our CHO-DG44
platform. RMCE application allows for multi-parallel
production of candidate material in the host cell and
process background used for the pharmaceutical cell lines.
Therefore, the molecular features of this material are
expected to match with material that will be derived from
a future producer cell line.
Generation of the RMCE host cell line
A replaceable gfp gene cassette was established at random
chromosomal integration sites in CHO-DG44 cells. This
clone pool was subjected to a primary RMCE with a
secreted and complex glycosylated alpha1-antitrypsine
(A1AT) reporter. Resulting cells were screened for A1AT
producers that have undergone a successful cassette
exchange. This strategy allows for selection of a RMCE
host cell line that combines transgene expression from
highly active genomic loci with superior processing and
secretion capabilities.
Strategy for routine RMCE application
The selected RMCE host cell line is susceptible for cassette
exchange with any desired target gene and candidate pro-
tein. Successful cassette exchange is enforced by promoter
trap and a well defined selection system (Figure 1A).
For RMCE application the promoterless target gene
encoding for the candidate protein is cloned into a target
vector where it is linked to a selection marker via an IRES
element. Upon successful cassette exchange, the target
and marker gene will be activated by a promoter residing
at the targeting locus. In addition, a second inactive mar-
ker gene (lacking an ATG) that resides also at the host
genome, but downstream of the replaceable gene cassette
will be activated. The target vector is introduced together
with a vector encoding the flp recombinase into the
RMCE host cell line. The use of heterospecific FRT sites
prevents from simple re-excision of the gene cassette.
A robust protocol provides for efficient RMCE
RMCE application results in cell populations showing
comparable expression levels of the newly introduced
genes as exemplified for individual RMCEs with a gfp
reporter and different selection formats (Figure 1B).
Also, a homogenous expression was observed within the
individual RMCE derived populations after drug selection.
Efficient RMCE application is supported by a fine tuned
and robust protocol that can be applied in T-flasks or
multiwell formats.
Evaluation studies: RMCE application with
monoclonal antibody and fusion proteins
RMCE was applied to a monoclonal antibody and single
cell clones have been generated from the RMCE derived
population. Those clones were analyzed together with the
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original population in fed batch culture using ProBioGen’s
chemical defined platform medium and process (Figure
1C). The RMCE derived population yielded in harvest
titers of 0.5 g/L matching the titers obtained for individual
clones. Consequently, after drug selection the cells can be
directly used for material production. Single cell cloning is
not required!
In a second study two variants of a soluble receptor-Fc
fusion protein were analyzed for manufacturability. Over
a number of individual RMCEs variant #1 was expressed
at a ~2-fold higher rate. In a fed batch process the differ-
ence was maintained yielding in final titers of 1.2 g/L for
variant #1 (Figure 1D). The 2-3-fold outperformance of
variant #1 was confirmed in classic cell line development.
RMCE facilitates streamlined generation of stable
cell lines and POC material production
At minimal effort RMCE application allows for stream-
lined generation of stable cell lines and production of
POC material (Figure 1E). Applying a single RMCE
within only 2 weeks a suspension culture is available for
scale-up and production. Compared to transient proto-
cols production runs can easily be repeated at any time
and scale.
Figure 1 A: RMCE Strategy for routine RMCE application in the selected CHO-DG44 RMCE host cell line. M = selection marker,
haat = A1AT gene. B: GFP expression of cell populations derived from multiple RMCEs and selection formats. C: RMCE with a monoclonal
antibody. Fed batch of the direct RCME derived population and three individual RMCE clones derived from original RMCE population. D: RMCE
with two variants of a soluble receptor-Fc fusion protein. Exemplary fed batch process for the both RMCE derived Fc fusion protein variants.
E: Timescale of routine RMCE Application.
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Conclusions
A robust protocol provides for efficient and reproducible
RMCE application for antibodies and single chain
proteins.
At minimal effort RMCE application enables fast and
multi-parallel evaluation of complex biological drug
candidates.
RMCE application allows for streamlined production
of candidate material in the background of ProBioGen’s
CHO-DG44 platform.
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